Categories
Blood Cancer

An overview of CAR-T therapy in DLBCL and MCL [Video]

Peter Riedell, MD, University of Chicago Medicine, Chicago, IL, comments on the key topics of a talk designed to provide oncologists and bone marrow transplant (BMT) specialists with an overview of CAR-T therapy in diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). The presentation recapitulated data on the three approved CAR-T products in DLBCL in the third-line setting, axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel), as well as data from the three pivotal trials comparing these CAR-T therapies to standard of care (SOC) in second line in DLBCL. Advances in MCL were also highlighted and included data showing the benefits of brexucabtagene autoleucel (brexu-cel) in these patients. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

Categories
Blood Cancer

Updates in CAR-T for non-Hodgkin lymphoma [Video]

In this video, Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, summarizes the key updates in CAR-T therapy for the treatment of non-Hodgkin lymphoma. Dr Collins highlights three studies from the 2021 ASH conference that focus on CAR-T therapy in first relapse for B-cell lymphoma: ZUMA-7, BELINDA, and TRANSFORM (NCT03391466, NCT03570892, NCT03575351). In his discussion, Dr Collins discusses and compares the results and subtle differences in these studies, including primary endpoints and outcomes. Following this, Dr Collins focuses his interest on the ZUMA-12 study (NCT03761056), explaining the methodology and results. This interview took place at the 63rd ASH Annual Meeting and Exposition, Atlanta, 2021.

Categories
Blood Cancer

Lymphoma highlights from ASH 2021 [Video]

Amitkumar Mehta, MD, UAB School of Medicine, Birmingham, AL, comments on his highlights in the field of lymphoma presented at ASH 2021, including the Phase III POLARIX trial (NCT03274492) of polatuzumab vedotin (R-CHP) in diffuse large B-cell lymphoma (DLBCL). Dr Mehta additionally talks on the ZUMA-7 (NCT03391466), TRANSFORM (NCT03575351), BELINDA (NCT03570892), and ELARA (NCT03568461) trials, which all assessed chimeric antigen receptor (CAR) T-cell therapies, as well as bispecific antibodies such as glofitamab and mosunetuzumab. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

Updates in CAR-T for non-Hodgkin lymphoma [Video]

In this video, Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, summarizes the key updates in CAR-T therapy for the treatment of non-Hodgkin lymphoma. Dr Collins highlights three studies from the 2021 ASH conference that focus on CAR-T therapy in first relapse for B-cell lymphoma: ZUMA-7, BELINDA, and TRANSFORM (NCT03391466, NCT03570892, NCT03575351). In his discussion, Dr Collins discusses and compares the results and subtle differences in these studies, including primary endpoints and outcomes. Following this, Dr Collins focuses his interest on the ZUMA-12 study (NCT03761056), explaining the methodology and results. This interview took place at the 63rd ASH Annual Meeting and Exposition, Atlanta, 2021.

Categories
Blood Cancer

Second-line CAR-T therapy in B-cell lymphoma [Video]

Peter M. Riedell, MD, University of Chicago Medicine, Chicago, IL, shares updates from the Phase III ZUMA-7 trial (NCT03391466) of the anti CD19 axicabtagene ciloleucel (axi-cel), a chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL). A superior event-free survival and overall survival were reported in the axi-cel arm and the findings corroborate with data from the Phase III TRANSFORM trial (NCT03575351), demonstrating the potential of CAR T-cell therapy as a second-line option for LBCL. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

The role of CAR-T therapy in hematologic malignancies [Video]

Michael Bishop, MD, University of Chicago, Chicago, IL, describes advances in chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies. Data from the JULIET (NCT02445248), TRANSFORM (NCT03575351), BELINDA (NCT03570892), ZUMA-1 (NCT02348216), and ZUMA-7 (NCT03391466) trials have demonstrated CAR T-cell therapy as a promising frontline therapy in non-Hodgkin lymphoma. Dr Bishop additionally highlights updates in multiple myeloma and acute lymphoblastic leukemia (ALL), as well as strategies to manage CAR T-cell toxicity. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.